Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend

Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) announced a 9% increase in its quarterly dividend, now set at 12 cents ($0.12) per share, payable on March 16, 2022. This marks the fourth consecutive quarterly dividend declaration, positioning the annual dividend rate for 2022 at 48 cents ($0.48) per share. CEO Michael Goettler expressed satisfaction with the company's operational momentum and commitment to returning capital to shareholders. The record date for this dividend is February 24, 2022.

Positive

• 9% increase in quarterly dividend to $0.12 per share.
• Annual dividend rate for 2022 set at $0.48 per share.
• CEO highlighted strong operational momentum.

Negative

• None.

PITTSBURGH, Jan. 6, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on Tuesday, January 4, its Board of Directors approved a 9% increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of 12 cents ($0.12) per share on outstanding common stock. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2022 is 48 cents ($0.48) per share.

The dividend will be payable on March 16, 2022 to shareholders of record at the close of business on February 24, 2022.  

"We have been pleased with our strong underlying business performance and operational momentum and remain committed to returning capital to shareholders," said Michael Goettler, Chief Executive Officer of Viatris.

About Viatris 
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars, and a variety of over-the-counter consumer products. With a global workforce of approximately 38,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube. 

Forward Looking Statement
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements that Viatris has declared a dividend of 12 cents ($0.12) per share of common stock payable on March 16, 2022 to shareholders of record at the close of business on February 24, 2022; at this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2022 is 48 cents ($0.48) per share; and that we have been pleased with our strong underlying business performance and operational momentum and remain committed to returning capital to shareholders. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to: the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; the integration of Mylan N.V. and Pfizer Inc.'s Upjohn business (the "Upjohn Business"), which combined to form Viatris (the "Combination") and the implementation of our global restructuring initiatives being more difficult, time consuming or costly than expected, or being unsuccessful; the ability to achieve expected benefits, synergies, and operating efficiencies in connection with the Combination or its restructuring initiatives within the expected timeframe or at all; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations, including our operations in China; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management; and the other risks Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-announces-9-dividend-increase-fourth-consecutive-quarterly-dividend-301455089.html

SOURCE Viatris Inc.

FAQ

What is the new dividend amount declared by VTRS?

Viatris declared a new quarterly dividend of 12 cents ($0.12) per share.

When will the dividend payment for VTRS be made?

The dividend payment will be made on March 16, 2022.

What is the record date for VTRS's dividend?

The record date for the dividend is February 24, 2022.

What is the annual dividend rate for VTRS in 2022?

The annual dividend rate for 2022 is set at 48 cents ($0.48) per share.

How many consecutive quarterly dividends has VTRS declared?

Viatris has declared dividends for four consecutive quarters.